Nudging Patients to Increase Shingles Vaccination
Conditions: Shingles; Vaccination Behavior; Behavior, Health Interventions: Behavioral: Reminder Sponsors: Geisinger Clinic; Massachusetts Institute of Technology; National Bureau of Economic Research, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury
Conditions: Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury Interventions: Biological: IncobotulinumtoxinA; Biological: Placebo Sponsors: Merz Therapeutics GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
MORRISVILLE, N.C., May 30, 2023. Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in the Company ' s... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 30, 2023 Category: Pharmaceuticals Source Type: clinical trials
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Conditions: Herpes Zoster (HZ); Shingles; Infectious Disease Interventions: Biological: JCXH-105; Biological: Active Control (Shingrix) Sponsors: Immorna Biotherapeutics, Inc.; ICON plc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 23, 2023 Category: Research Source Type: clinical trials
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
Conditions: Shingles; Herpes Zoster Infection; Human Interventions: Biological: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection; Biological: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection; Biological: Candidate 2: PF-07921188: VZV modRNA Suspension for Injection; Biological: Candidate 3: PF-07921186: VZV modRNA Su spension for Injection; Biological: Shingrix; Biological: Selected Vaccine Candidate group (Dose level, Schedule); Biological: Shingrix - SSB Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2023 Category: Research Source Type: clinical trials
